Cargando…

JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL

ETP-ALL (Early T cell Progenitor Acute Lymphoblastic Leukemia) represents a high-risk subtype of T cell acute lymphocytic leukemia (T-ALL). Therapeutically, ETP-ALL patients frequently relapse after conventional chemotherapy highlighting the need for alternative therapeutic approaches. Using our ZEB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benyoucef, Aissa, Haigh, Katharina, Cuddihy, Andrew, Haigh, Jody J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712096/ https://www.ncbi.nlm.nih.gov/pubmed/36229595 http://dx.doi.org/10.1038/s41375-022-01716-9

Ejemplares similares

Unveiling the complexity of transcription factor networks in hematopoietic stem cells: implications for cell therapy and hematological malignancies
por: Benyoucef, Aissa, et al.
Publicado: (2023)

Mutational landscape of adult ETP-ALL
por: Neumann, Martin, et al.
Publicado: (2013)

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation
por: Chen, Juan, et al.
Publicado: (2023)

The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL
por: Tavakoli Shirazi, Paniz, et al.
Publicado: (2019)

Origins of ETP leukemia
por: Booth, Christopher A. G., et al.
Publicado: (2018)

On the Origin of ETP Leukemias
por: Tesio, Melania
Publicado: (2018)

Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity
por: Wang, Jueqiong, et al.
Publicado: (2021)

Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL
por: Fransecky, L., et al.
Publicado: (2016)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) – Mechanisms and Opportunities
por: Bernt, Kathrin M., et al.
Publicado: (2016)

Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant
por: McEwan, Ashley, et al.
Publicado: (2020)

In Silico Integration of Transcriptome and Interactome Predicts an ETP-ALL-Specific Transcriptional Footprint that Decodes its Developmental Propensity
por: Mukherjee, Soumyadeep, et al.
Publicado: (2022)

Emerging Necessity of Myeloid Mutational Analysis in Early T-cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL)
por: Tariq, Hamza, et al.
Publicado: (2023)

An ETP model (exclusion-tolerance-progression) for multi drug resistance
por: Kannan, Subburaj
Publicado: (2005)

Origin and distribution of epipolythiodioxopiperazine (ETP) gene clusters in filamentous ascomycetes
por: Patron, Nicola J, et al.
Publicado: (2007)

The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China
por: Xiao, Jinyan, et al.
Publicado: (2022)

End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL-may be the way forward
por: Patra, Pritish Chandra, et al.
Publicado: (2023)

A Selective Phenelzine Analogue Inhibitor of Histone Demethylase LSD1
por: Prusevich, Polina, et al.
Publicado: (2014)

Synergistic antitumor effect of 5-fluorouracil with the novel LSD1 inhibitor ZY0511 in colorectal cancer
por: Peng, Wen, et al.
Publicado: (2020)

Etp1 confers arsenite resistance by affecting ACR3 expression
por: Romero, Antonia M, et al.
Publicado: (2022)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction
por: Belteki, Gusztav, et al.
Publicado: (2005)

Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction
por: Belteki, Gusztav, et al.
Publicado: (2005)

ABT-737, a Bcl-2 Selective Inhibitor, and Chloroquine Synergistically Kill Renal Cancer Cells
por: Yin, Pei, et al.
Publicado: (2016)

Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core
por: Grimm, Juliane, et al.
Publicado: (2022)

BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells
por: Inoue, Chisato, et al.
Publicado: (2018)

Histone Demethylase LSD1 is required for Germinal Center formation and BCL6-driven lymphomagenesis
por: Hatzi, Katerina, et al.
Publicado: (2018)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S, et al.
Publicado: (2018)

Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
por: Ishikawa, Y, et al.
Publicado: (2017)

Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells
por: Roy, Koushik, et al.
Publicado: (2008)

T255. WHO PARTICIPATED IN FAMILY WORK IN THE US RAISE-ETP FIRST EPISODE SAMPLE?
por: Glynn, Shirley, et al.
Publicado: (2018)

F249. FAMILY BURDEN IN THE US RAISE-ETP PROGRAM: TREATMENT EFFECTS AND PREDICTORS
por: Glynn, Shirley, et al.
Publicado: (2018)

Correlation to FVIII:C in Two Thrombin Generation Tests: TGA-CAT and INNOVANCE ETP
por: Ljungkvist, Marcus, et al.
Publicado: (2017)

GeneMark-ETP: Automatic Gene Finding in Eukaryotic Genomes in Consistency with Extrinsic Data
por: Bruna, Tomas, et al.
Publicado: (2023)

Structure–Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD2
por: Niwa, Hideaki, et al.
Publicado: (2022)

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway
por: Luo, Fan, et al.
Publicado: (2021)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Synergistic Re-Activation of Epigenetically Silenced Genes by Combinatorial Inhibition of DNMTs and LSD1 in Cancer Cells
por: Han, Han, et al.
Publicado: (2013)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

Antitumor activity of LSD1 inhibitors in lung cancer
por: Mohammad, Helai P., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nca1hreerbdk861i2gpnd4016f